Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 10/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22768560 | 0.83 | NNMT (0.46) | SYKPDCD1LG2CD274L3MBTL1POLB | |
| SCHEMBL2415642 | 0.74 | PLK1 (0.36) | SYKPOLBKDM4E | |
| SCHEMBL22842972 | 0.73 | PDCD1LG2 (0.36) | SYKPDCD1LG2CD274CA1CA2 | |
| SCHEMBL19237081 | 0.73 | CD274 (0.46) | PDCD1LG2CD274L3MBTL1 | |
| SCHEMBL31523455 | 0.73 | CD274 (0.46) | PDCD1LG2CD274L3MBTL1 | |
| SCHEMBL25009567 | 0.71 | PDCD1LG2 (0.37) | SYKPDCD1LG2CD274POLBTDP1 | |
| SCHEMBL8737283 | 0.71 | LPAR1 (0.40) | SYKPDCD1LG2CD274KDM4E | |
| SCHEMBL12049970 | 0.71 | POLB (0.47) | PDCD1LG2CD274POLBTDP1 | |
| SCHEMBL8738081 | 0.71 | PDCD1LG2 (0.37) | SYKPDCD1LG2CD274CA1CA2 | |
| SCHEMBL2411089 | 0.70 | GRM4 (0.38) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | SYK 4540/4885PDCD1LG2 2542/4885CD274 2609/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | SYK 4540/4885PDCD1LG2 2542/4885CD274 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.